trending Market Intelligence /marketintelligence/en/news-insights/trending/hD_SvfepaGueGfH5wB_Rrw2 content esgSubNav
In This List

US FDA approves 2 Teva Pharmaceutical asthma inhalers

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


US FDA approves 2 Teva Pharmaceutical asthma inhalers

The U.S. FDA approved two Teva Pharmaceutical Industries Ltd. asthma inhalers.

The inhalers, AirDuo RespiClick and ArmonAir RespiClick, will be available for adolescent and adult patients via prescription later this year.